12/20
07:30 pm
elab
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
Medium
Report
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
12/20
07:35 am
elab
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada [Yahoo! Finance]
Low
Report
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada [Yahoo! Finance]
12/20
07:30 am
elab
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
Low
Report
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
12/9
08:00 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
Medium
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
12/6
07:30 am
elab
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
Low
Report
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
12/4
08:12 am
elab
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division [Yahoo! Finance]
Low
Report
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division [Yahoo! Finance]
12/4
08:00 am
elab
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
Medium
Report
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
11/22
06:24 pm
elab
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance [Yahoo! Finance]
11/22
06:23 pm
elab
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
Medium
Report
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
11/22
05:01 pm
elab
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess [Yahoo! Finance]
High
Report
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess [Yahoo! Finance]
11/22
05:00 pm
elab
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
High
Report
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
11/17
09:46 am
elab
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]
11/14
02:35 pm
elab
CORRECTION - Elevai Labs Inc.
Low
Report
CORRECTION - Elevai Labs Inc.
11/14
09:17 am
elab
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]
High
Report
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]
11/14
09:08 am
elab
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
High
Report
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
11/4
05:48 pm
elab
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]
11/4
05:45 pm
elab
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Low
Report
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
10/22
09:59 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity [Yahoo! Fina
Low
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity [Yahoo! Fina
10/22
09:54 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
Medium
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
10/21
07:30 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
High
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
10/4
05:16 pm
elab
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock [Yahoo! Finance]
10/4
05:08 pm
elab
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
Medium
Report
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
10/3
03:45 pm
elab
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Neutral
Report
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
10/3
10:01 am
elab
Elevai Bioscience up on portfolio expansion with new filings for muscle loss treatment in obese patients [Seeking Alpha]
Low
Report
Elevai Bioscience up on portfolio expansion with new filings for muscle loss treatment in obese patients [Seeking Alpha]
10/3
07:30 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
High
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations